（於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-135 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月2日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) ...

Market Performance - The Hang Seng Index closed at 25,617, up 2.15% for the day and up 27.70% year-to-date [1] - The Hang Seng Tech Index rose 2.20% to 5,798, with a year-to-date increase of 29.79% [1] - The Shanghai Composite Index increased by 0.46% to 3,875, with a year-to-date rise of 15.63% [1] Currency and Commodity Overview - The Renminbi Index stood at 96.570, showing a 0.90% increase over the last month but a 3.33% decline over six months [2] - Brent crude oil price was $68.170 per barrel, down 0.86% over the last month and down 2.68% over six months [2] - Gold prices increased by 3.26% over the last month, reaching $3,473.27 per ounce, and rose 20.07% over six months [2] Company News - Alibaba's stock surged by 18.50% to HKD 137.10 after several major banks raised their target prices following the company's earnings report [5][21] - The pharmaceutical sector saw significant gains, with CSPC Pharmaceutical rising 9.14% and WuXi Biologics increasing by 8.37% [5][21] - Hengrui Medicine's HRS9531 injection received acceptance for market approval from the National Medical Products Administration, targeting long-term weight management for adults with obesity-related conditions [12] Economic Indicators - China's August Manufacturing PMI rose to 50.5, surpassing market expectations of 49.5, indicating a recovery in manufacturing activity driven by increased new orders [13][14] - Hong Kong's retail sales value for July increased by 1.8% year-on-year, falling short of the expected 2.5% growth [10][11] IPO and Market Trends - Recent IPOs have shown strong performance, with Jiaxin International Resources listing at a price of HKD 33.82, reflecting a first-day gain of 177.84% [28] - The upcoming IPO of Daxing Technology is set for September 9, 2025, with a proposed offer price of HKD 49.5 [28] Sector Performance - The biotechnology sector led gains with a 3.58% increase, while the automotive sector saw a decline of 2.00% [24] - The pharmaceutical sector also performed well, contributing to the overall positive market sentiment [24]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of September 2, with Northeast Electric (00042) leading at a premium rate of 770.97% and CATL (03750) at the bottom with -13.13% [1][2] Summary by Category Top AH Premium Rates - Northeast Electric (00042) has a premium rate of 770.97% with H-share priced at 0.310 HKD and A-share at 2.25 CNY [1] - Andeli Juice (02218) follows with a premium rate of 244.59%, H-share at 16.530 HKD and A-share at 47.55 CNY [1] - Hongye Futures (03678) ranks third with a premium rate of 244.34%, H-share at 4.150 HKD and A-share at 11.93 CNY [1] Bottom AH Premium Rates - CATL (03750) shows a negative premium rate of -13.13%, with H-share at 417.600 HKD and A-share at 302.87 CNY [1] - Heng Rui Medicine (01276) has a premium rate of 2.47%, H-share at 80.500 HKD and A-share at 68.87 CNY [1] - Midea Group (00300) has a premium rate of 5.09%, with H-share at 86.800 HKD and A-share at 76.16 CNY [1] Premium Deviation Values - Jinli Permanent Magnet (06680) has the highest deviation value at 33.67%, with a premium rate of 116.12% [1] - Changfei Optical Fiber (06869) follows with a deviation value of 31.15% and a premium rate of 137.88% [1] - Andeli Juice (02218) also ranks high with a deviation value of 27.61% [1] Bottom Premium Deviation Values - BYD (01211) has the lowest deviation value at -54.46%, with a premium rate of 18.94% [2] - Great Wall Motors (02333) has a deviation value of -23.27% [2] - Longpan Technology (02465) shows a deviation value of -21.31% [2]

Group 1: Hong Kong Stock Market Performance - Midea Group (00300) increased nearly 3% with Q2 revenue of 123.9 billion yuan, a year-on-year increase of 11.0%, and net profit of 13.59 billion yuan, up 15.1%. This marks the company's first interim dividend of 5 yuan per 10 shares (tax included) [2] - Sanofi (02257) saw a midday increase of over 12% as its mid-term shareholder loss narrowed by 91%, with STP705 expected to complete commercialization within the year [2] - Ocean Park (02255) rose nearly 3% in early trading, but reported a 14.2% year-on-year decline in revenue to 686 million yuan, with a loss of approximately 296 million yuan due to decreased visitor numbers and consumer spending [2] Group 2: Company Highlights - InnoCare Pharma (02577) increased over 6% with a sales revenue of 553 million yuan, a year-on-year growth of 43.4%, and a gross margin of 6.8%, marking a significant improvement of 28.4 percentage points [3] - Geekplus (02590) rose over 5%, achieving over 30% year-on-year revenue growth as a leader in global warehouse fulfillment AMR [3] - China Nonferrous Mining (01258) increased over 3.8% due to rising copper prices improving mid-term performance, with ongoing resource expansion and acquisitions [3] Group 3: Other Notable Movements - Hengrui Medicine (01276) rose over 1.5% after receiving drug registration approval for EZH2 inhibitor [3] - Horizon Robotics (09660) fell nearly 1% despite exceeding market expectations in revenue, with Goldman Sachs maintaining a positive outlook on HSD system mass production [3] - BYD Electronics (00285) dropped over 0.5% with a nearly 14% year-on-year increase in net profit, accelerating its layout in AI data centers and robotics [3] - Shandong Gold (01787) fell nearly 2% as it plans to raise approximately 3.9 billion HKD through a discounted placement to repay company debts [3]

Core Viewpoint - Heng Rui Medicine (01276) has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, Zemeituosita Tablets (SHR2554), aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [1] Group 1: Company Developments - Heng Rui Medicine's stock rose over 3%, specifically by 3.21%, reaching HKD 82.05 with a trading volume of HKD 206 million [1] - Zemeituosita Tablets is the first self-developed EZH2 inhibitor in China, marketed under the name Airiqing [1] - The drug effectively inhibits both wild-type and mutant EZH2 enzyme activity, reactivating tumor suppressor genes and improving the tumor microenvironment [1] Group 2: Research and Development - The total R&D investment for Zemeituosita Tablets has reached approximately RMB 213 million [1]

Group 1 - The company, Heng Rui Medicine, has received conditional approval from the National Medical Products Administration for its innovative drug, Zemeituosita Tablets (SHR2554), which is intended for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [1] - Zemeituosita Tablets is noted as the first independently developed EZH2 inhibitor in China [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the drug listing application of HRS9531 injection, indicating progress in the company's product pipeline [1] Group 1: Product Information - HRS9531 injection is intended for long-term weight management in adults with a body mass index (BMI) of ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with at least one weight-related comorbidity, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver [1]

Group 1 - The core point of the article is that Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, for adult patients with relapsed or refractory peripheral T-cell lymphoma who have previously undergone at least one line of systemic therapy [1] Group 2 - SHR2554 tablets are the first self-developed EZH2 inhibitor in China, representing a new, efficient, and selective oral EZH2 inhibitor [2] - The global sales of Tazverik, an EZH2 inhibitor developed by Epizyme, are projected to reach approximately $51 million in 2024 [2] - The cumulative R&D investment for SHR2554 tablets has reached approximately 213 million yuan [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 孫飄揚先生 中國上海 2025年9月1日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-134 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月1日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-133 ...